Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

Stefano Luminari, Luigi Marcheselli, Stefano Sacchi, Sacchi Samantha Pozzi, Alessia Bari, Fiorella Llariucci, Caterina Stelitano, Francesco Angrilli, Antonio Lazzaro, Luca Baldini

Research output: Contribution to journalArticle

Abstract

Background: Recent experience has suggested that there has been a stepwise improvement in the survival outcomes of patients who have follicular lymphoma with the introduction of new treatment options. In the current study, the authors report the results of 2 subsequent phase 2 trials of 238 previously untreated patients. METHODS: In a trial of bleomycin, epidoxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP) plus fludarabine, rnitoxantrone, and dexamethasone (FND), 144 patients received 2 BACOP treatments followed by 4 FND treatments. In a trial of BACOP plus fludarabine and rituximab (FR), 94 patients received 3 BACOP treatments followed by 4 FR treatments. RESULTS: The complete remission

Original languageEnglish
Pages (from-to)1906-1913
Number of pages8
JournalCancer
Volume115
Issue number9
DOIs
Publication statusPublished - May 1 2009

Keywords

  • Anthracycline
  • Fludarabine
  • Follicular lymphoma
  • Non-hodgkin lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Luminari, S., Marcheselli, L., Sacchi, S., Pozzi, S. S., Bari, A., Llariucci, F., Stelitano, C., Angrilli, F., Lazzaro, A., & Baldini, L. (2009). Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. Cancer, 115(9), 1906-1913. https://doi.org/10.1002/cncr.24222